Virax Biolabs (VRAX) Total Liabilities (2021 - 2026)
Virax Biolabs (VRAX) posted quarterly Total Liabilities of $989832.0 for Q1 2026, up 2.6% year-over-year from $964750.0 in Q1 2025, and up 2.6% quarter-over-quarter from $964750.0 in Q1 2025.
Virax Biolabs (VRAX) Total Liabilities (2021 - 2026) Analysis & Trends
Virax Biolabs' Total Liabilities history runs 6 years deep, the most recent figure standing at $989832.0 for Q1 2026.
- In Q1 2026, Total Liabilities rose 2.6% year-over-year to $989832.0; the TTM figure through Mar 2026 stood at $989832.0 (up 2.6% YoY), while the FY2026 annual figure was $989832.0, up 2.6% from the prior year.
- Total Liabilities for Q1 2026 stood at $989832.0, up from $964750.0 in the prior quarter.
- The five-year high for Total Liabilities was $9.4 million in Q3 2024, with the low at $345194.0 in Q1 2024.
- The 5-year median for Total Liabilities is $977291.0 (2025), against an average of $2.3 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities sank 62.0% in 2024, then surged 179.48% in 2025.
- Virax Biolabs' Total Liabilities stood at $1.2 million in 2022, then decreased by 27.06% to $908401.0 in 2023, then soared by 939.51% to $9.4 million in 2024, then plunged by 89.78% to $964750.0 in 2025, then gained by 2.6% to $989832.0 in 2026.
- Business Quant data shows VRAX's Total Liabilities at $989832.0 in Q1 2026, $964750.0 in Q1 2025, and $9.4 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - | 989,832.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 989,832.00 |
| Mar 31, 2025 | 964,750.00 |
| Sep 30, 2024 | 9.44 Mn |
| Mar 31, 2024 | 345,194.00 |
| Mar 31, 2023 | 908,401.00 |
| Mar 31, 2022 | 1.25 Mn |
| Mar 31, 2021 | 871,435.00 |